Page last updated: 2024-10-21

edelfosine and Bilateral Wilms Tumor

edelfosine has been researched along with Bilateral Wilms Tumor in 1 studies

edelfosine: RN given refers to parent cpd
edelfosine : A racemate comprising equimolar amounts of (R)- and (S)-edelfosine.
1-octadecyl-2-methylglycero-3-phosphocholine : A glycerophosphocholine that is glycero-3-phosphocholine substituted at positions 1 and 2 by octadecyl and methyl groups respectively.

Research Excerpts

ExcerptRelevanceReference
"Paediatric solid tumours exhibit steep dose-response curves to alkylating agents and are therefore considered candidates for high-dose chemotherapy and autologous stem cell support."1.32Preferential inactivation of paediatric solid tumour cells by sequential exposure to Merocyanine 540-mediated photodynamic therapy and Edelfosine: implications for the ex vivo purging of autologous haematopoietic stem cell grafts. ( Anderson, GS; Miyagi, K; Sampson, R; Sieber, F; Tsujino, I, 2003)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Anderson, GS1
Tsujino, I1
Miyagi, K1
Sampson, R1
Sieber, F1

Other Studies

1 other study available for edelfosine and Bilateral Wilms Tumor

ArticleYear
Preferential inactivation of paediatric solid tumour cells by sequential exposure to Merocyanine 540-mediated photodynamic therapy and Edelfosine: implications for the ex vivo purging of autologous haematopoietic stem cell grafts.
    Journal of photochemistry and photobiology. B, Biology, 2003, Volume: 69, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Dose-Response Relationship,

2003